Lamar Odom’s Ups and Downs Through the Years: Khloe, Drugs, Kids

first_img“I’m just a different man now. You know what’s so crazy that you say that because I remember when I came out of the coma after the drug overdose], and I moved in the house in Calabasas in the same housing community that she lives in,” he told Us. “Because I was still damn near fried or just basically getting over being fried, I didn’t even know how to show her that I was empathetic, you know what I’m saying, and sorry and that I still loved her. I didn’t know how to go about it.”Scroll through to revisit Odom’s ups and downs: Life has been a roller coaster for Lamar Odom.The former professional basketball player’s career began in 1999 when he was drafted by the Los Angeles Clippers. Odom went on to play for the Miami Heat, Los Angeles Lakers and Dallas Mavericks over his nearly 15-year career in the NBA.- Advertisement – – Advertisement – “There’s no doubt in my mind that she’s the best mother ever because she took care of a 29-year-old man like he was a baby,” Odom told Us Weekly in May 2019. “I had every candy, cookie, juice, champagne, ice cream. I didn’t need anything and that’s just on the small scale. She made this room for me in our home. She’s an incredible homemaker, but all women in that family are.”He added at the time that he will “always” love Kardashian, who briefly withdrew her divorce papers and took care of him after he almost died following an overdose at a brutal in Nevada in 2015.- Advertisement – Shortly before he found success on the basketball court, Odom welcomed his first child, a daughter named Destiny, with his then-girlfriend Liza Morales. The twosome also share son Lamar Jr., who was born in 2002. Before Odom and Morales called it quits in 2006, she gave birth to a son named Jayden, who passed away at 6 months old of sudden infant death syndrome (SIDS).Odom’s personal life started making headlines in 2009 when he met Khloé Kardashian. After a whirlwind romance, the pair tied the knot in September 2009. Following a successful wedding episode of Keeping Up With the Kardashians, Odom and Kardashian launched a spinoff called Khloé & Lamar in 2011. The reality series ran for two seasons.While the twosome called it quits in December 2013 after four years of marriage amid Odom’s substance abuse issues, the athlete has only had kind words to say about his ex-wife, who shares daughter True with ex Tristan Thompson.- Advertisement –last_img read more

New innovative Driving Module programme for Students at Carndonagh Community School

first_imgCarndonagh Community School has launched a new innovative driving module programme for their Leaving Applied Certificate (LAC) students. This new programme is the first of its kind in Donegal and indeed in Ireland and will be facilitated by the Pro Social Drivers Programme. This programme is about educating our young people on driving safely on the roads.Deputy Principal at Carndonagh Community School Owen McConway, is delighted to be hosting this Pilot Driver Education Programme with their LCA students and explains that there are three main pillars within the module: (1) Prosocial Drivers Councillors; (2) Presentations from Gardai; and (3) Practical preparation and Theory Preparation. Speaking at the launch Mr. McConway said they believe this is an important initiative in educating young people in keeping our roads safe, before they start driving.“The Programme will be evaluated at the end and will inform the Pro Social Drivers Programme and Donegal County Council on the possible roll-out of the initiative to other schools and youth organisations”.The Pro Social Ireland Drivers Programme is a road safety initiative set up in Letterkenny in 2012 initially with the aim of rehabilitating dangerous drivers using a cognitive behavioural approach.The students in Carndonagh will attend modules designed to address particular problem areas such as emotional control, social responsibility, driving under the influence and the consequences of anti-social behaviour while driving. Mick Quinlivan, Pro Social Drivers Programme, stated “we are delighted to be given the opportunity to deliver the programme and we would like to thank the Donegal Road Safety Working Group for all their assistance to date and we look forward to working with Carndonagh Community School as we develop and expand the programme further.” Garda Inspector Michael Harrison said “in my opinion this course is saving lives on our roads and I am delighted to see it as part of the schools programme in Carndonagh. Reducing the number of deaths and injuries on Donegal’s roads is a responsibility we all share”.Senator Pádraig Mac Lochlainn said “for years, the news from Donegal in terms of road safety has been often devastating. It is brilliant to have this dedicated group of professionals from Donegal delivering an innovative programme to the students in Carndonagh which will change their driving habits and without doubt, will save lives”.The Cathaoirleach of Donegal County Council, Cllr Gerry McMonagle outlined Donegal County Council’s and the DRSWG;s commitment to working with local communities in Donegal in promoting road safety and said “the Pro-Social Drivers Programme targets high risk groups of drivers who are initially identified through the justice and legal system but we now have an opportunity to deliver this programme to young people before they start their driving career.”Brian O’Donnell, Road Safety Officer, Donegal County Council stated that “the Donegal Road Safety Working Group are delighted that the Pro Social Drivers Programme have been given the opportunity to deliver this unique programme to students in Carndonagh Community School. As a wider group we are all committed to making a combined ongoing effort to make our roads safer for all who use them.”This initiative is being piloted in conjunction with Donegal County Council and Pro Social Drivers Programme and is funded by the North Inishowen School Completion Programme. The Pro Social Ireland Drivers Programme is a road safety initiative set up in Letterkenny in 2012. After liaising with the probation services in Letterkenny, which expressed a keen desire to see a reduction in the number of motorists who fitted the profile of repeat offenders, the Pro-Social Drivers Programme was formed in Letterkenny. This cognitive behavioural approach continues to go from strength to strength in achieving some very positive outcomes. The programme, which aims at rehabilitating dangerous drivers, won the National Supreme Award in 2016 at the Road Safety Authority ‘Leading Lights in Road Safety’ awards.New innovative Driving Module programme for Students at Carndonagh Community School was last modified: October 5th, 2017 by StephenShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window)last_img read more

Experimental Huntington disease drug reduces toxic protein newly published data confirm

first_img John Lehmann Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Experimental Huntington disease drug reduces toxic protein, newly published data confirm Email The authors report, however, that symptoms of the disease were generally unchanged when the data were considered for each of five patient groups that received different doses, and “no meaningful differences were observed between patients who received placebo and patients who received HTTRx, regardless of the dose level.”Now, all eyes are on a pivotal clinical trial that aims to enroll 660 people with Huntington disease. The first patient was enrolled in January, and the last patient data are expected to be collected in March 2022. Large enough and long enough to allow scientists to measure the drug’s impact on symptoms of the slowly progressive disease, the study should show whether the drug can deliver on its promise of slowing or stopping the course of the devastating disease.Running the key trial is Roche of Basel, Switzerland, which licensed HTTRx from its developer, Ionis Pharmaceuticals of Carlsbad, California, in December 2017, and renamed it RG6042. Click to view the privacy policy. Required fields are indicated by an asterisk (*)center_img The data behind the promising trial of a drug that blocks the production of a mutant protein that causes brain damage in people with Huntington disease—an inherited and ultimately fatal neurological disorder—were published today in The New England Journal of Medicine, giving an official imprimatur to news that first electrified the community of patients with the disease 17 months ago.The results, originally announced in December 2017, were published alongside an editorial that called the trial “pathbreaking.” The new paper reports that the drug, a short stretch of synthetic DNA called HTTRx that blocks the production of the mutant protein huntingtin, is safe in humans; no serious adverse events were reported by the 46 people who participated in the trial. (Last summer, Science wrote in depth about the first participant, Michelle Dardengo.)The results also provide details behind the source of excitement about the trial: that HTTRx reduced levels of huntingtin in the cerebrospinal fluid (CSF) that bathes the spinal cord—a proxy, it is hoped, for what is happening in the brain—by amounts that had reversed Huntington-like motor and cognitive symptoms in mice. And the reductions in the mutant protein in the CSF of patients were dose-dependent: Through a range of dosing levels, the bigger the dose, the more the reduction of the mutant protein. By Meredith WadmanMay. 6, 2019 , 3:40 PM Sign up for our daily newsletter Get more great content like this delivered right to you! Country Michelle Dardengo was the first patient enrolled in the first human trial of a promising new therapy against Huntington disease.last_img read more